EyePoint Pharmaceuticals(US:EYPT)2026-03-05 21:06Clinical Trials and Product Development - The fiscal year ended December 31, 2025, was marked by the completion of pivotal Phase 3 clinical trials for DURAVYU, with data expected to begin in mid-2026 [438]. - Enrollment in the pivotal Phase 3 trials for wet AMD was completed on July 29, 2025, with the first patient dosed in the DME program in February 2026 [438]. - DURAVYU demonstrated a +7.1 letter BCVA gain and a 76-micron CST reduction at week 24 in the Phase 2 VERONA clinical trial, with a supplement-free rate of 73% compared to 50% for aflibercept [443]. - DURAVYU's Phase 2 VERONA trial in DME met both primary and secondary endpoints, showing sustained improvement in vision and safety [443]. - The company anticipates the first patient dosing in the Phase 3 COMO and CAPRI trials for DME in the first quarter of 2026 [443]. - The company presented multiple datasets at the ARVO Annual Meeting, highlighting DURAVYU's potential in various retinal disease indications [443]. Financial Performance - Total revenues decreased by $11.9 million, or 28%, to $31.4 million in 2025 compared to $43.3 million in 2024 [457]. - Product sales, net decreased by $1.6 million, or 50%, to $1.6 million in 2025 due to the termination of the ANI commercial supply agreement [458]. - License and collaboration agreement revenues decreased by $21.8 million, or 57%, to $16.7 million in 2025 primarily due to the recognition of remaining deferred revenue [459]. - Royalty income increased by $11.4 million, or 708%, to $13.0 million in 2025, attributed to the recognition of deferred SWK royalty income [460]. - Net loss increased by $101.1 million, or 77%, to $232.0 million in 2025 from $130.9 million in 2024 [457]. Expenses and Cash Flow - Research and development expenses increased by $88.1 million, or 66%, to $221.0 million in 2025, driven by ongoing DURAVYU Phase 3 clinical trials [462]. - Total operating expenses increased by $85.7 million, or 45%, to $274.8 million in 2025 compared to $189.1 million in 2024 [457]. - Operating cash outflows totaled $240.1 million in 2025, primarily due to a net loss of $232.0 million [476]. - Cash, cash equivalents, and investments in marketable securities totaled $306.1 million at December 31, 2025, expected to fund operations into Q4 2027 [472]. Financing Activities - The underwritten public offering of 11,000,000 shares at $12.00 per share raised approximately $162.1 million in net proceeds after underwriting discounts [440]. - The company completed a public offering with gross proceeds of $172.5 million, selling 12,875,000 shares at $12.00 per share [467]. - The company raised $173.4 million from the issuance of 12,875,000 shares of common stock in a follow-on offering in 2025 [480]. - In 2024, the company raised $163.3 million from the issuance of 14,636,363 shares of common stock in a follow-on offering [480]. - Net cash provided by financing activities for the year ended December 31, 2025 totaled $173.7 million, an increase from $164.0 million in 2024 [479]. Corporate Developments - The company completed a buyout of its 3.125% perpetual royalty obligation for a one-time payment of $17.25 million, eliminating future royalty payments starting January 1, 2025 [439]. - The company reached an agreement in principle with the DOJ to settle matters related to its sales practices for approximately $4.7 million plus interest [444]. - The company appointed Michael Campbell as Chief Commercial Officer on February 18, 2026, to strengthen its commercial strategy [443]. - The company does not have any off-balance sheet arrangements that would materially affect its financial condition [479]. - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures [481].